Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for moderate and severe diffuse axonal injury in adult men
IRCT20190717044248N6Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Diffuse axonal injury (DAI) comparing Melatonin with Placebo (2 arms). Primary endpoints: Glasgow Outcome Scale at 6 months, Functional Independence Measure at 6 months and 1 more. Started Oct 2022; status: completed.
02
Drugs
melatonin
03
Conditions
Diffuse axonal injury (DAI)
Beyond the preview
Go deeper on IRCT20190717044248N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190717044248N6.